Literature DB >> 24226631

Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations.

E Manara1, V Bisio1, R Masetti2, V Beqiri1, R Rondelli2, G Menna3, C Micalizzi4, N Santoro5, F Locatelli6, G Basso1, M Pigazzi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24226631     DOI： 10.1038/leu.2013.339

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.

Authors:  Tobias M Kohl; Susanne Schnittger; Joachim W Ellwart; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Blood       Date:  2004-12-23       Impact factor: 22.113

2.  KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.

Authors:  Akira Shimada; Tomohiko Taki; Ken Tabuchi; Akio Tawa; Keizo Horibe; Masahiro Tsuchida; Ryoji Hanada; Ichiro Tsukimoto; Yasuhide Hayashi
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

3.  Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).

Authors:  Ursula Creutzig; Martin Zimmermann; Jean-Pierre Bourquin; Michael N Dworzak; Christine von Neuhoff; Annette Sander; André Schrauder; Andrea Teigler-Schlegel; Jan Stary; Selim Corbacioglu; Dirk Reinhardt
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

4.  Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.

Authors:  B F Goemans; C M Zwaan; M Miller; M Zimmermann; A Harlow; S Meshinchi; A H Loonen; K Hählen; D Reinhardt; U Creutzig; G J L Kaspers; M C Heinrich
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

Review 5.  The core-binding factor leukemias: lessons learned from murine models.

Authors:  James R Downing
Journal:  Curr Opin Genet Dev       Date:  2003-02       Impact factor: 5.578

6.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.

Authors:  Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; Phoenix A Ho; Rong Zeng; Yaddanapudi Ravindranath; Gary Dahl; Norman J Lacayo; David Becton; Myron Chang; Howard J Weinstein; Betsy Hirsch; Susana C Raimondi; Nyla A Heerema; William G Woods; Beverly J Lange; Craig Hurwitz; Robert J Arceci; Jerald P Radich; Irwin D Bernstein; Michael C Heinrich; Soheil Meshinchi
Journal:  Blood       Date:  2010-01-07       Impact factor: 22.113

7.  Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia.

Authors:  Andrea Pession; Riccardo Masetti; Carmelo Rizzari; Maria Caterina Putti; Fiorina Casale; Franca Fagioli; Matteo Luciani; Luca Lo Nigro; Giuseppe Menna; Concetta Micalizzi; Nicola Santoro; Anna Maria Testi; Marco Zecca; Andrea Biondi; Martina Pigazzi; Sergio Rutella; Roberto Rondelli; Giuseppe Basso; Franco Locatelli
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

8.  Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

Authors:  Ursula Creutzig; Martin Zimmermann; Jean-Pierre Bourquin; Michael N Dworzak; Gudrun Fleischhack; Norbert Graf; Thomas Klingebiel; Bernhard Kremens; Thomas Lehrnbecher; Christine von Neuhoff; Jörg Ritter; Annette Sander; André Schrauder; Arend von Stackelberg; Jan Starý; Dirk Reinhardt
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

9.  Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.

Authors:  L-Y Shih; D-C Liang; C-F Huang; Y-T Chang; C-L Lai; T-H Lin; C-P Yang; I-J Hung; H-C Liu; T-H Jaing; L-Y Wang; T-C Yeh
Journal:  Leukemia       Date:  2007-10-25       Impact factor: 11.528

10.  Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

Authors:  Peter Paschka; Juan Du; Richard F Schlenk; Verena I Gaidzik; Lars Bullinger; Andrea Corbacioglu; Daniela Späth; Sabine Kayser; Brigitte Schlegelberger; Jürgen Krauter; Arnold Ganser; Claus-Henning Köhne; Gerhard Held; Marie von Lilienfeld-Toal; Heinz Kirchen; Mathias Rummel; Katharina Götze; Heinz-August Horst; Mark Ringhoffer; Michael Lübbert; Mohammed Wattad; Helmut R Salih; Andrea Kündgen; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2012-10-31       Impact factor: 22.113
View more
  23 in total

1.  Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline.

Authors:  Valérie de Haas; Nofisat Ismaila; Anjali Advani; Daniel A Arber; Raetasha S Dabney; Dipti Patel-Donelly; Elizabeth Kitlas; Rob Pieters; Ching-Hon Pui; Kendra Sweet; Ling Zhang
Journal:  J Clin Oncol       Date:  2018-12-03       Impact factor: 44.544

2.  Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial.

Authors:  M Tokumasu; C Murata; A Shimada; K Ohki; Y Hayashi; A M Saito; J Fujimoto; K Horibe; M Nagao; H Itoh; Y Kamikubo; H Nakayama; A Kinoshita; D Tomizawa; T Taga; A Tawa; S Tanaka; T Heike; S Adachi
Journal:  Leukemia       Date:  2015-05-15       Impact factor: 11.528

3.  Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients.

Authors:  Fan Zhou; Fen Zhou; Mengyi Du; Lin Liu; Tao Guo; Linghui Xia; Runming Jin; Yu Hu; Heng Mei
Journal:  Int J Hematol       Date:  2019-08-22       Impact factor: 2.490

4.  Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia.

Authors:  Soheil Meshinchi; Jessica A Pollard; Katherine Tarlock; Todd A Alonzo; Yi-Cheng Wang; Robert B Gerbing; Rhonda Ries; Michael R Loken; Laura Pardo; Tiffany Hylkema; Jason Joaquin; Leela Sarukkai; Susana C Raimondi; Betsy Hirsch; Lillian Sung; Richard Aplenc; Irwin Bernstein; Alan S Gamis
Journal:  Clin Cancer Res       Date:  2019-06-10       Impact factor: 12.531

Review 5.  Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities.

Authors:  Chandrima Sinha; Lea C Cunningham; Paul P Liu
Journal:  Semin Hematol       Date:  2015-04-07       Impact factor: 3.851

6.  Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.

Authors:  Kim Klein; Gertjan Kaspers; Christine J Harrison; H Berna Beverloo; Ardine Reedijk; Mathilda Bongers; Jacqueline Cloos; Andrea Pession; Dirk Reinhardt; Martin Zimmerman; Ursula Creutzig; Michael Dworzak; Todd Alonzo; Donna Johnston; Betsy Hirsch; Michal Zapotocky; Barbara De Moerloose; Alcira Fynn; Vincent Lee; Takashi Taga; Akio Tawa; Anne Auvrignon; Bernward Zeller; Erik Forestier; Carmen Salgado; Walentyna Balwierz; Alexander Popa; Jeffrey Rubnitz; Susana Raimondi; Brenda Gibson
Journal:  J Clin Oncol       Date:  2015-11-16       Impact factor: 44.544

Review 7.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Authors:  C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

8.  CREB engages C/EBPδ to initiate leukemogenesis.

Authors:  C Tregnago; E Manara; M Zampini; V Bisio; C Borga; S Bresolin; S Aveic; G Germano; G Basso; M Pigazzi
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528

Review 9.  Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Authors:  Wenlan Chen; Hui Xie; Hongxiang Wang; Li Chen; Yi Sun; Zhichao Chen; Qiubai Li
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

10.  Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531.

Authors:  Andrew P Voigt; Lisa Eidenschink Brodersen; Todd A Alonzo; Robert B Gerbing; Andrew J Menssen; Elisabeth R Wilson; Samir Kahwash; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Soheil Meshinchi; Denise A Wells; Michael R Loken
Journal:  Haematologica       Date:  2017-09-07       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.